300 related articles for article (PubMed ID: 23238013)
41. [Expressions of angiogenesis-related factors: CD105, EphA2 and EphrinA1 in laryngeal squamous cell carcinoma and clinical implication].
Su J; Ji XB; Xie JH; Li W
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 51(12):929-936. PubMed ID: 27978884
[No Abstract] [Full Text] [Related]
42. EphA2 as a promoter of melanoma tumorigenicity.
Margaryan NV; Strizzi L; Abbott DE; Seftor EA; Rao MS; Hendrix MJ; Hess AR
Cancer Biol Ther; 2009 Feb; 8(3):279-88. PubMed ID: 19223760
[TBL] [Abstract][Full Text] [Related]
43. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
44. EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice.
Whitehurst KS; Chan VA; Estes HK; Valsaraj S; Kent S; Sharma UM; Chase RC; Bhuiyan M; Virag JAI
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823610
[TBL] [Abstract][Full Text] [Related]
45. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility.
Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846
[TBL] [Abstract][Full Text] [Related]
46. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Fukuchi M; Nakajima M; Kuwano H
Int J Cancer; 2003 Feb; 103(5):657-63. PubMed ID: 12494475
[TBL] [Abstract][Full Text] [Related]
47. Tobacco smoke induces epithelial barrier dysfunction via receptor EphA2 signaling.
Nasreen N; Khodayari N; Sriram PS; Patel J; Mohammed KA
Am J Physiol Cell Physiol; 2014 Jun; 306(12):C1154-66. PubMed ID: 24717580
[TBL] [Abstract][Full Text] [Related]
48. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
49. The SAM domain inhibits EphA2 interactions in the plasma membrane.
Singh DR; Ahmed F; Paul MD; Gedam M; Pasquale EB; Hristova K
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):31-38. PubMed ID: 27776928
[TBL] [Abstract][Full Text] [Related]
50. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
51. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade.
Pratt RL; Kinch MS
Oncogene; 2002 Oct; 21(50):7690-9. PubMed ID: 12400011
[TBL] [Abstract][Full Text] [Related]
52. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
53. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
[TBL] [Abstract][Full Text] [Related]
54. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level.
Mo J; Zhao X; Dong X; Liu T; Zhao N; Zhang D; Wang W; Zhang Y; Sun B
Cell Oncol (Dordr); 2020 Aug; 43(4):655-667. PubMed ID: 32291572
[TBL] [Abstract][Full Text] [Related]
55. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
[TBL] [Abstract][Full Text] [Related]
56. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
Xu Q; Lin WC; Petit RS; Groves JT
Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062
[TBL] [Abstract][Full Text] [Related]
57. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
58. The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).
Foveau B; Boulay G; Pinte S; Van Rechem C; Rood BR; Leprince D
J Biol Chem; 2012 Feb; 287(8):5366-78. PubMed ID: 22184117
[TBL] [Abstract][Full Text] [Related]
59. Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells.
Jung EH; Lee HN; Han GY; Kim MJ; Kim CW
Cell Biochem Funct; 2016 Apr; 34(3):149-57. PubMed ID: 26923195
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size.
Zapata-Mercado E; Biener G; McKenzie DM; Wimley WC; Pasquale EB; Raicu V; Hristova K
J Biol Chem; 2022 Oct; 298(10):102370. PubMed ID: 35970390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
